It is known that MEK inhibitors, such as AZD6244 and trametinib, have been developed in clinical studies in cancer, and have the potential to suppress KRAS mutant tumor rely on MAPK signaling pathway [7]. This evidence concerns the gene MAP2K7 and cancer.